Fractional Laser Resurfacing Patents: Who Leads, Where Gaps Are 2026
- 45.5% concentration at the top. The five leading assignees hold 429 of 942 records in scope — a field where a handful of players occupy nearly half the claim space.
- Filings cooled -15% from 2021 to 2024. 39 records in 2021 fell to 33 in 2024, the last year the trend can be read as complete; 2025-2026 figures are still filling in under publication lag.
- Electrotherapy claims sit second to core surgical/diagnostic art. A61N (electrotherapy & radiation) appears on 28.7% of records behind A61B at 66.9%, with laser-specific H01S art present on only 5.9%.
Filing growth compares 2021 (39 records) with 2024 (33) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 942 records in scope (CR5), not by the ranked leaders only.
What the fractional laser resurfacing patent record shows
Fractional laser resurfacing sits at the intersection of dermatologic surgery, electrotherapy/radiation devices and cosmetic formulation. The 942 records in scope span microthermal zone geometry, coverage-density control, pulse-energy tuning, scanner patterning and the downstream management of healing time and hyperpigmentation risk. The bulk of the art is classified as surgical/diagnostic apparatus (A61B) rather than as laser hardware (H01S), which tells a practical story: most of the patented value is in how the energy is delivered and controlled on tissue, not in the laser source itself.
Filing activity built through the late 2010s, peaked in 2022, and has since eased against a backdrop where publication lag makes the very latest years look thinner than they will end up being. Receiving-office data shows the United States as the dominant venue, with Europe, the WIPO/PCT route, Israel, Australia and Canada following at meaningfully lower volumes — a filing footprint typical of a device category with a concentrated set of clinical-device manufacturers protecting core markets first.
Filing trends and technology composition
Trend and classification data for the 942 records in scope, drawn directly from the underlying dataset.
Filings rose to a 2022 peak, then eased
Annual filings moved from 43 in 2017 to a peak of 51 in 2022. The most recent complete comparison — 39 records in 2021 against 33 in 2024 — shows a -15% shift over that three-year span. 2025 and 2026 figures are still incomplete under the roughly 18-month publication lag and should not be read as a continued decline.
Surgical apparatus dominates; laser-source claims are a minority
A61B (diagnosis & surgery) appears on 66.9% of the 942 records, far ahead of A61N electrotherapy/radiation at 28.7% and A61K medicinal preparations at 22.3%. H01S, the class covering lasers and stimulated emission themselves, appears on only 5.9% of records — most protection in this field covers how the energy is applied and managed, not the laser source.
Shares are the percentage of the 942 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Fractional Laser Resurfacing with Eureka
This page is one run against one query. Ask Eureka your own question about fractional laser resurfacing and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
Microjet Drug Delivery System with Enhanced Drug Penetration Performance by Fractional Laser Pre-ablation
Discloses a microjet drug delivery system that pairs a laser generator with a microjet injector: a pressure chamber sealed by an elastic membrane sits adjacent to a drug chamber with a micro-nozzle, so that fractional-laser pre-ablation of the skin is combined with mechanical drug ejection to improve penetration into tissue.Filed by SNU R&DB Foundation, published 2019-08-22 as US20190255253A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050049582A1 | Method and apparatus for fractional photo therapy of skin | 500 |
| 2 | US20050222565A1 | Method and apparatus for dermatological treatment and tissue reshaping | 321 |
| 3 | US20060095096A1 | Interchangeable tips for medical laser treatments and methods for using same | 275 |
| 4 | US20120064136A1 | Anti-aging and wrinkle treatment methods using nanoemulsion compositions | 215 |
| 5 | US20140079686A1 | Methods For Treating Baldness And Promoting Hair Growth | 198 |
| 6 | US20060155266A1 | Method and apparatus for dermatological treatment and fractional skin resurfacing | 188 |
| 7 | US6315772B1 | Laser assisted pharmaceutical delivery and fluid removal | 182 |
| 8 | US6514278B1 | Method and device for the superficial heating of tissue | 177 |
| 9 | US20050010198A1 | Removable tip for laser device with transparent lens | 173 |
| 10 | US20110009737A1 | Method and apparatus for dermatological treatment and tissue reshaping | 172 |
Citation counts reward older filings that have had more time to accumulate citations inside this searched corpus; treat them as a signal of influence on the field, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and trend data mean for filing strategy
Three figures from this dataset matter more than the rest for anyone deciding where to file next.
Core claim space is held by a small group
The five leading assignees account for 429 of the 942 records in scope. That level of concentration means core mechanisms — microthermal zone patterning, pulse-energy control loops, scanner geometries — are more likely to sit on prior art from an incumbent than to be open ground.
Filing pace has eased from its 2022 peak
Annual filings peaked at 51 in 2022. The last comparison that avoids publication-lag distortion, 2021 against 2024, shows a -15% change. That is a cooling of pace at the top of the field, not evidence the technology is exhausted — later years are still filling in.
Delivery and tissue interaction, not the laser itself, carries the claims
A61B (surgical/diagnostic apparatus) touches two-thirds of records while H01S (laser hardware) touches under 6%. Most defensible IP in this space is written around how energy is delivered, sequenced and monitored on skin, not around novel laser sources.
US filing leads by a wide margin
The United States receives more filings than the EPO, WIPO/PCT and other national offices combined among the receiving-office counts given. Applicants protecting core mechanisms in this field prioritise the US market first, with EPO and PCT filings used for broader coverage.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to fractional laser resurfacing, with the prior art for and against each one.
Who holds the claim space, and where it thins out
The ranked leaders capture nearly half of all records, but momentum among even the top names has slowed in the most recent complete years — a signal worth reading carefully given publication lag.
A single leader holds a clear volume edge
The top-ranked assignee's record count is well ahead of fifth place at 45 and tenth place at 23, indicating one organisation has built a substantially broader portfolio than any single competitor behind it.
Beyond the top ten, filings fragment quickly
Ten assignees combined hold 558 of 942 records, 59.2% of the field. The remaining 90 ranked companies split the rest, meaning most organisations in this space hold only a handful of families each.
Even leading assignees show thin recent-year counts
Several of the most active historical filers show zero or near-zero filings in the latest year, with year-over-year changes as steep as -100% for some. Given publication lag, this understates true recent activity rather than confirming a pullback.
| Assignee | Recent year | YoY |
|---|---|---|
| RegenX Sci Inc | 2 | -33% |
| The General Hospital Corp | 0 | — |
| Cytrellis Biosystems | 0 | -100% |
| Reliant Technologies LLC | 0 | — |
| Cynosure Inc | 0 | -100% |
| TRIA BEAUTY INC | 0 | — |
| Lumenis Ltd | 0 | — |
| Lumenis Be Ltd | 0 | — |
Where to take this analysis
This landscape is a starting point for freedom-to-operate and whitespace decisions, not a substitute for a formal search.
Run a claims-level freedom-to-operate check
Concentration among the leading assignees means core mechanisms in microthermal zone control and scanner patterning likely sit on active claims. A citation-anchored review of the highest-cited records is the fastest way to map what is actually blocked.
Explore claim analysis in EurekaTrack recent-year filings past the publication lag
The 2025-2026 figures in this dataset are still incomplete. Monitoring new publications as they land is the only reliable way to catch whether the 2021-2024 slowdown continues or reverses.
Set up filing alerts in EurekaTest a first claim in an under-claimed branch
Coverage-density feedback control and combined microjet drug delivery show thin representation relative to the core surgical classes. Drafting around these branches now, while filing density is low, is cheaper than contesting occupied claim space later.
Draft and stress-test claims in EurekaCommon questions about fractional laser resurfacing patents
The assignee ranking for this dataset of 942 records shows one organisation clearly ahead of the field, with a record count well above the fifth-ranked and tenth-ranked assignees. The top five assignees combined hold 429 records, 45.5% of all records in scope, meaning core mechanisms are concentrated rather than evenly spread. Anyone entering this space should expect to negotiate around or design past claims held by this small leading group before looking at the long tail of smaller filers.
Annual filings rose through the late 2010s and peaked at 51 records in 2022. The most reliable recent comparison, 2021 against 2024, shows a -15% change, a real but modest cooling rather than a collapse. Figures for 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so it is too early to call this a sustained decline.
Classification data shows A61B, covering surgical and diagnostic apparatus, present on 66.9% of the 942 records in scope, making it by far the dominant category. A61N, electrotherapy and radiation therapy, follows at 28.7%, and A61K medicinal preparations at 22.3%. Notably, H01S, the class specific to lasers and stimulated emission hardware, appears on only 5.9% of records, indicating that most patented value lies in delivery and tissue-interaction methods rather than in the laser source itself.
Relative to the dominant surgical and electrotherapy classes, several specific sub-areas show thinner coverage: coverage-density feedback control, hyperpigmentation-risk scoring, adaptive scanner-pattern optimisation, combined microjet drug delivery with laser pre-ablation, and post-treatment healing-time monitoring. These are not proven-empty spaces, but the composition data suggests less claim density than the core A61B and A61N territory, making them reasonable candidates for a first, carefully scoped claim.
US20190255253A1, filed by SNU R&D Foundation and published 2019-08-22, discloses a microjet drug delivery system that combines a laser generator with a mechanical injector: a pressure chamber sealed by an elastic membrane sits next to a drug chamber with a micro-nozzle, so that fractional-laser pre-ablation of skin is paired with active drug ejection to improve penetration. It matters because it sits at the specific intersection of fractional laser pre-treatment and drug delivery hardware, a combination that anyone building a laser-assisted delivery device needs to review directly rather than assume is covered by broader resurfacing patents.
Research Fractional Laser Resurfacing in depth with Eureka
Go past this page: query the whole fractional laser resurfacing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.